Therapeutic Advances in Psychopharmacology
September 1, 2025
Sally Meikle, Olivia Carter, Paul Liknaitzky et al.
2 citations
In an open-label pilot trial, two 25 mg doses of psilocybin combined with psychotherapy produced a clinically meaningful reduction in depressive symptoms at 3 weeks in people with treatment-resistant depression. The average improvement was sustained at 20 weeks, but individual responses varied: two participants showed lasting benefit, three relapsed, and two did not improve. Mindset before dosing, spiritual experiences, and perceptual changes during the session predicted treatment trajectory, whereas treatment expectations did not. No serious adverse events occurred. The findings support further research into tailoring psilocybin therapy to individual variability.
bioRxiv Preprint Server
July 16, 2025
Borjan Milinkovic, Anil K. Seth, Lionel Barnett et al.
2 citations
preprint
Consciousness depends on neural activity across many scales. A new measure, dynamical independence (DI), quantifies these multi-scale relationships. Applying DI to EEG data from people under three anaesthetics, the authors found that propofol and xenon—which abolish conscious report—produce more emergent but highly variable dynamic structure, indicating fragmented macroscopic organisation. Ketamine, which preserves dream-like states, shows reduced overall emergence but partial preservation of macroscopic structure similar to wakefulness. Regional brain contributions varied. The results reveal drug-specific reconfigurations of emergent dynamics, dissociate the amount of emergence from its organisation, and caution against equating emergence with consciousness level.
Psychiatric Research and Clinical Practice
July 23, 2024
Chiranth Bhagavan, Richard Kanaan, Olivia Carter et al.
2 citations
A protocol for the first study testing whether movement tasks can be performed safely while under the influence of psilocybin. Twelve healthy participants will each receive three different doses (5 to 20 mg) in a randomized, blinded order at least one week apart. Motor function, safety, brain activity via fMRI, and subjective experience will be measured during the acute drug effects. The study aims to inform future research combining psychedelics with motor retraining for conditions involving motor dysfunction.
BMJ open
May 11, 2026
Julia Colcott, Alexandre A Guerin, Olivia Carter et al.
A new tool, the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET), was developed to systematically capture side effects during MDMA-assisted psychotherapy. Experts in MDMA-AP and neuropsychopharmacology participated in a two-round online Delphi process to refine a list of 165 items across four questionnaires covering screening, baseline, medication session days, and follow-up. The tool aims to improve safety monitoring and build a more robust evidence base on the tolerability of MDMA-AP for research and clinical use.
medRxiv Preprint Server
April 17, 2026
Chiranth Bhagavan, Orwa Dandash, Olivia Carter et al.
preprint
Psilocybin, a classic psychedelic, acutely alters brain functional connectivity, and these changes are linked to therapeutic doses and subjective effects. Some evidence indicates that such changes persist beyond the acute drug administration period. However, the effects of lower doses on sustained connectivity changes remain unclear.
September 30, 2025
Toby J. Woods, Andrew W. Corcoran, Olivia Carter et al.
preprint
A 15-minute session of Stillness Meditation, which involves skillfully doing nothing, is calming, pleasant, and easy for meditation-naive adults, not aversive as earlier research suggested. In a randomized trial with 165 participants, those practicing Stillness Meditation reported the session as calm, pleasant, and easy, and showed increases in heart rate variability and interbeat interval from baseline. While focused attention led to higher self-reported calm than Stillness Meditation or an audiobook, there were no differences in easiness, pleasantness, or cardiac measures between groups. The findings validate Stillness Meditation as a tool for studying pure consciousness.
The International Journal of Neuropsychopharmacology
August 1, 2025
Susan Meikle, Olivia Carter, Paul Liknaitzky et al.
A small pilot trial of psilocybin with psychotherapy for treatment-resistant depression found a clinically meaningful reduction in depressive symptoms three weeks after the second dose, with an average improvement of 7.14 points on the depression scale and a large effect size. However, individual responses varied widely: two participants showed lasting improvement, three relapsed, and two saw no substantial benefit. Mindset before dosing and spiritual or perceptual experiences during the session predicted treatment trajectory, but prior expectations did not. The study supports further research into tailoring psychedelic therapy to individual differences.